Aliqopa

Copanlisib (trade name Aliqopa /ælkop/ AL-ih-KOH-pah;[1] codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.[2] Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells. Efficacy resulting in the approval of copanlisib was based on the subgroup of 104 patients with follicular lym... [wikipedia]